
US gene therapy company Seawolf Therapeutics has entered into a multi-target research partnership and exclusive licensing agreement with Sanofi. The deal, valued at up to $1.2bn, focuses on developing treatments for bleeding disorders and other undisclosed indications. Under the terms, Seawolf is eligible for research, development, and commercial milestone payments, as well as tiered royalties on future sales of any resulting therapies.
The alliance coincides with Seawolf emerging from stealth mode with $100m in financing to advance its pipeline of DNA-based medicines. This funding includes seed financing led by founding investor Versant Ventures, followed by a Series A round supported by MPM BioImpact, Novartis Venture Fund, and Versant Ventures. Other participants in the financing included Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, and Sixty Degree Capital.
Seawolf will use the capital to progress candidates built upon its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform. The technology uses lipid nanoparticles to transport immune-quiet DNA encoding a therapeutic transgene directly into cell nuclei, aided by an auxiliary factor. This nuclear delivery aims to achieve stable, long-term therapeutic protein expression, overcoming the transient activity associated with standard RNA-based therapies. Unlike viral vectors, the nanoparticle delivery system allows repeated administration to adjust or supplement dosing over time. Seawolf has shown proof of concept for the approach in preclinical murine and non-human primate models of metabolic and rare diseases. In addition to collaborating with Sanofi, the company is advancing an internal lead programme targeting metabolic diseases.
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.